



Financial Statements
for the 1st quarter of fiscal year ending March 31, 2021
(From Apr. 1, 2020 to Jun. 30, 2020)

Summary of consolidated results

JMS Co., Ltd.

Company Code No. 7702

August 7, 2020

Highlights in Business Results



(unit: JPY million)

	Apr. - Jun. 2019 Results	Apr. - Jun. 2020 Results	Diff.	Year-over-Year
Net sales	13,494	13,579	85	0.6%
Operating profit	91	630	539	586.6%
Ordinary profit	187	685	498	265.9%
Profit attributable to owners of parent	48	659	611	— %
Basic earnings per share	JPY 1.98	JPY 27.05	---	---

Exchange Rate (average during period)	US Dollar	JPY 109.90	JPY 107.62
	Euro	JPY 125.15	JPY 120.11
	Singapore Dollar	JPY 80.61	JPY 76.21

**Increased in sales.
Increased in profit (2nd straight year).**


Sales	Japan	-Increased sales of Examination Gloves and Closed Drug Mixing/Infusion System "NEO SHIELD" -Decreased sales of Infusion Sets	Overseas	-Increased sales of Blood Bags and AV Fistula Needle
	Profit	-The influence of sales increase, the improved sales cost ratio and decreased selling, general and administrative expenses, resulting in increase of the operating profit and the ordinary profit -The subsidy income of extraordinary income resulted in increase of the profit attributable to owners of parent		

Summary by segment (geographical area)

(unit: JPY million)

Japan

■ Sales incl. internal transaction
■ Sales for third party
— Profit




[Sales] Increased sales of Examination Gloves and Closed Drug Mixing/Infusion System “NEO SHIELD” were offset by decreased sales of Infusion Sets, reducing net sales.

[Ordinary Income] Despite the influence of decrease sales, improved sales cost ratio and decreased selling, general and administrative expenses resulted in a profit growth.

Singapore

■ Sales incl. internal transaction
■ Sales for third party
— Profit




[Sales] Increased sales of Blood bags for West Asia market raised net sales.

[Ordinary Income] The influence of sales increase resulted in a profit growth.

*This segment includes Indonesia local subsidiary.

China

■ Sales incl. internal transaction
■ Sales for third party
— Profit



[Sales] Decreased sales of Infusion Sets for the Japan market due to production transfer to the plant in Philippines reduced net sales.


[Ordinary Income] Despite the influence of decrease sales, the decrease of labor cost resulted in a profit growth.

Summary by segment (geographical area)

(unit: JPY million)

Philippines

- Sales incl. internal transaction
- Sales for third party
- Profit




[Sales] Due to a temporary suspension of production activities under the influence of COVID-19, decreased sales of Infusion Sets for the Japan market reduced net sales.

[Ordinary Income] Due to decreased selling, general and administrative expenses, reduced loss.

Germany

- Sales incl. internal transaction
- Sales for third party
- Profit




[Sales] Increased sales of AV Fistula Needle raised net sales.

[Ordinary Income] The influence of sales increase resulted in a profit growth.

Others


- Sales for third party
- Profit




*This segment includes business activity of subsidiaries in Japan, United States, South Korea and Thailand.

Sales by Business Segment


Apr. – Jun. 2019
 Apr. – Jun. 2020



Sales change by Region (Customer's Location)




(unit: JPY million)



Selling, General and Admin. Expenses



(unit: JPY million)



(unit: JPY million)

	Apr. - Jun. 2019	Apr. - Jun. 2020	Diff.	Year-over-Year
Labor Cost	1,487	1,446	(41)	(2.8)%
Transport	397	434	36	9.1%
R & D	369	328	(41)	(11.2)%
Depreciation	89	84	(5)	(6.0)%
Others	1,017	853	(164)	(16.1)%
Total	3,362	3,146	(216)	(6.4)%


[Reasons for change]

Travel expenses and Clinical trial expense for the development of a new product decreased.

Ordinary profit : Compared with the previous year



(unit: JPY million)



Forecast for FYE Mar. 2021



(unit: JPY million)

	FYE Mar. 2020 Result	FYE Mar. 2021 Forecast	Year-over-Year
Net sales	58,569	59,500	1.6%
Operating profit	2,314	2,000	(13.6)%
Ordinary profit	2,672	2,200	(17.7)%
Profit attributable to owners of parent	1,977	1,600	(19.1)%
Basic earnings per share	JPY 81.12	JPY 65.62	---

Exchange Rate (average during period)	US Dollar	JPY 108.74	JPY 108
	Euro	JPY 122.07	JPY 120
	Singapore Dollar	JPY 79.28	JPY 78

- Received the "Silver Medal of Merit" from the Japanese Red Cross Society.
Jul. 2020
- Announcement of disposition of treasury shares as the stock compensation plan with transfer restrictions.
Jul. 2020
- Treatment for refractory skin ulcer using Platelet Collection Sets "CELLAID P Type" is now covered by insurance.
Apr. 2020





The Bridge to Good Health Care

The assessment figures described on this report are based on available information at this moment, including uncertain data. Actual results may be different from the figures.